The P2X7 receptor in infection and inflammation

F Di Virgilio, D Dal Ben, AC Sarti, AL Giuliani, S Falzoni - Immunity, 2017 - cell.com
Adenosine triphosphate (ATP) accumulates at sites of tissue injury and inflammation. Effects
of extracellular ATP are mediated by plasma membrane receptors named P2 receptors …

The P2X7 receptor in inflammatory diseases: angel or demon?

LEB Savio, P de Andrade Mello… - Frontiers in …, 2018 - frontiersin.org
Under physiological conditions, adenosine triphosphate (ATP) is present at low levels in the
extracellular milieu, being massively released by stressed or dying cells. Once outside the …

Purinergic signalling: therapeutic developments

G Burnstock - Frontiers in pharmacology, 2017 - frontiersin.org
Purinergic signalling, ie, the role of nucleotides as extracellular signalling molecules, was
proposed in 1972. However, this concept was not well accepted until the early 1990's when …

Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases

CA Dinarello, A Simon… - Nature reviews Drug …, 2012 - nature.com
Abstract Interleukin-1 (IL-1) is a highly active pro-inflammatory cytokine that lowers pain
thresholds and damages tissues. Monotherapy blocking IL-1 activity in autoinflammatory …

Ion channels in innate and adaptive immunity

S Feske, H Wulff, EY Skolnik - Annual review of immunology, 2015 - annualreviews.org
Ion channels and transporters mediate the transport of charged ions across hydrophobic
lipid membranes. In immune cells, divalent cations such as calcium, magnesium, and zinc …

Targeting the NLRP3 inflammasome in chronic inflammatory diseases: current perspectives

E Ozaki, M Campbell, SL Doyle - Journal of inflammation research, 2015 - Taylor & Francis
The inflammasome is a molecular platform formed by activation of an innate immune pattern
recognition receptor seed, such as NLRP3. Once activated, NLRP3 recruits the adapter ASC …

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

JS Smolen, R Landewé, FC Breedveld… - Annals of the …, 2014 - ard.bmj.com
In this article, the 2010 European League against Rheumatism (EULAR) recommendations
for the management of rheumatoid arthritis (RA) with synthetic and biological disease …

Structural basis for subtype-specific inhibition of the P2X7 receptor

A Karasawa, T Kawate - elife, 2016 - elifesciences.org
The P2X7 receptor is a non-selective cation channel activated by extracellular adenosine
triphosphate (ATP). Chronic activation of P2X7 underlies many health problems such as …

Inflammasomes: mechanisms of action and involvement in human diseases

D Bulté, C Rigamonti, A Romano, A Mortellaro - Cells, 2023 - mdpi.com
Inflammasome complexes and their integral receptor proteins have essential roles in
regulating the innate immune response and inflammation at the post-translational level. Yet …

P2X7 receptor: an emerging target in central nervous system diseases

B Sperlágh, P Illes - Trends in pharmacological sciences, 2014 - cell.com
The ATP-sensitive homomeric P2X7 receptor (P2X7R) has received particular attention as a
potential drug target because of its widespread involvement in inflammatory diseases as a …